Compass Pathways Aksje

Compass Pathways AAQS

AAQS av Compass Pathways (CMPS) per 21. aug. 2026 er 4. Forrige år var AAQS 4,00 — en endring på 0,00% (lavere).

AAQS

4

YoY

0,00%

Sist oppdatert:

Compass Pathways har en aktuell AAQS på 4. En høy AAQS kan sees på som et positivt tegn på at selskapet utvikler seg vellykket. Investorer kan forvente at selskapet er på riktig spor for å oppnå fortjeneste. På den andre siden er det viktig å se på AAQS for aksjen Compass Pathways i forhold til de inntjente overskuddene og andre selskaper i samme sektor. En høy AAQS er ingen absolutt garanti for en positiv fremtid. Det er bare slik man kan få et komplett bilde av selskapets ytelse. For å bedre vurdere utviklingen til selskapet, er det viktig å sammenligne AAQS med andre selskaper i samme bransje. Generelt bør investorer alltid vurdere AAQS til et selskap i sammenheng med andre nøkkeltall som fortjeneste, EBIT, kontantstrøm og andre for å treffe en velinformert investeringsbeslutning.
Access this data via the Eulerpool API

Compass Pathways Aksjeanalyse

Hva gjør Compass Pathways? Compass Pathways PLC is a leading company specializing in the development of groundbreaking therapies for the treatment of mental illnesses. The company was founded in 2016 and is headquartered in London. Its goal is to revolutionize the treatment of depression and other mental illnesses. The business model of Compass Pathways is based on researching psychedelics as a potential treatment for patients suffering from severe depression and anxiety disorders. The company uses innovative approaches to precisely study the effects of psychedelics on the human brain and develop new therapy concepts and products from that. An important area of Compass Pathways is clinical research. The company collaborates closely with leading research institutions to understand the impacts of psychedelics on the human brain. The research results are then used to develop innovative methods for therapeutic use of psychedelics. Another important area of Compass Pathways is the development of therapeutic products. The company has developed a patented process for producing psilocybin, a substance found in hallucinogenic mushrooms. This process achieves a very high purity of the substance, enabling precise dosing and better control of its effects. The flagship product of Compass Pathways is COMP360, a medication based on psilocybin that is being developed for the treatment of depression. The medication is currently in clinical Phase 2 trials, showing promising results. If COMP360 receives approval, it has the potential to drastically change the way we treat depression. Compass Pathways is also active in other areas. The company conducts a range of research projects related to various psychedelic substances, including LSD and other hallucinogens. Another important area of Compass Pathways is training therapists and other professionals in the use of psychedelic substances. The company offers relevant courses to promote understanding of the therapeutic use of psychedelics and enable their safe and effective application for patient treatment. Overall, Compass Pathways is a company focused on the development of groundbreaking therapies for mental illnesses. Through combining cutting-edge research, innovative products, and professional education, the company has the potential to revolutionize the way we treat mental illnesses. Compass Pathways er et av de mest populære selskapene på Eulerpool.

Ofte stilte spørsmål om Compass Pathways aksje

AAQS for Compass Pathways er 4 i 2026.

På Eulerpool finner du den komplette historiske utviklingen av AAQS Compass Pathways siden 2006 – med årlige verdier, diagrammer og detaljert analyse.

AAQS er en nøkkelindikator utviklet av AlleAktien.

AAQS er en indikator utviklet av AlleAktien.

Access this data via the Eulerpool API

Kvalitet — Compass Pathways

Alle nøkkeltall — Compass Pathways